Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684663 | 0.83 | FPR2 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2699177 | 0.81 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4686275 | 0.74 | F10 (0.47) | CTSGCMA1F10 | |
| SCHEMBL4679795 | 0.71 | F10 (0.47) | F10 | |
| SCHEMBL6988224 | 0.69 | F10 (0.47) | F10 | |
| SCHEMBL302217 | 0.68 | HTR2C (0.47) | KCNA5CTSGCMA1KCNH2 | |
| SCHEMBL4925756 | 0.68 | HTR2C (0.53) | MCOLN3 | |
| SCHEMBL4680343 | 0.68 | F10 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6983760 | 0.67 | F10 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3808387 | 0.66 | CTSB (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | PSEN1 2345/4885PSEN2 3790/4885APH1B 609/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | PSEN1 2345/4885PSEN2 3790/4885APH1B 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.